Parallel Trade

Parallel trade of medicinal products in the internal market is possible because of the rules in the internal market for the exhaustion of trademark rights. As of the transition period, the rules for exhaustion of trademark rights in the EU no longer apply in respect of products placed on the UK market.

Article 76(4) of Directive 2001/83/EC no longer applies to medicinal products sourced in the United Kingdom for the purpose of parallel distribution in EU. The transfer of parallel distribution notices to another entity is not foreseen and a change of address is possible only in case the legal entity remains the same.

Source: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/notice-stakeholders-withdrawal-united-kingdom-eu-rules-medicinal-products-human-use-veterinary_en

Latest Resources

  • Blogs

    Brexit: The MHRA and The Proposed eSubmission Portal

    Read More
  • White Papers

    Impact of COIVD – 19 on FMCG Supply Chain Regulatory Compliance

    Read More
  • Case Studies

    Expedited Product Classification and NIOSH Certification for N95 Respirator

    Read More

What our Clients Say?

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Quick Inquiry
x